Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

UroGen Pharma Ltd. (NASDAQ: URGN) has unveiled the design of its pivotal uTRACT Registry study at the 2025 American Society ...

At a median follow-up of 60.7 months, patients in the combination arm of enzalutamide + leuprolide had significantly superior 5-year metastasis free survival rates (87.3% versus 71.4%; HR: 0.42, 95% ...

A three-year exercise program improved survival in colon cancer patients and kept disease at bay, a first-of-its-kind ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

US researchers, who assessed the health records of more than 2.4million adults, said they cannot be sure exactly why the ...

In addition, the study's results suggested a substantial overall survival (OS) benefit with the exercise regimen as well, ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Emerging research is uncovering how a fiber-rich, whole-foods-based diet may help support better outcomes for patients ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.